The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kondratieva T.B.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia

Popova L.V.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia

Bokarev I.N.

kafedra gospital'noĭ terapii Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Non-vitamin K antagonist oral anticoagulants for heart diseases

Authors:

Kondratieva T.B., Popova L.V., Bokarev I.N.

More about the authors

Journal: Therapeutic Archive. 2017;89(9): 120‑127

DOI: 10.17116/terarkh2017899120-127

Views: 19546

Downloaded: 1247

Download PDF (RU)
Contact the author
Table of contents

NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS FOR HEART DISEASES
NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS FOR HEART DISEASES

To cite this article:

Kondratieva TB, Popova LV, Bokarev IN. Non-vitamin K antagonist oral anticoagulants for heart diseases. Therapeutic Archive. 2017;89(9):120‑127. (In Russ.)
https://doi.org/10.17116/terarkh2017899120-127

МСФ на ЯМ
Close metadata

Non-vitamin K antagonist oral anticoagulants (NОАСs) are highly effective drugs that prevent venous thrombosis and stroke in atrial fibrillation. Their use has difficulties that are associated with the need for laboratory control and with the influence of many factors on the activity of these medications. The emerged direct oral anticoagulants have some advantages over NOACs. Nevertheless, there are a number of pathological conditions, in which NOACs remain first-line drugs. These include prosthetic mechanical heart valves, a glomerular filtration rate less than 60 mL/min/1.73 m2, and left atrial thrombus.

Keywords:

non-vitamin K antagonist oral anticoagulants
warfarin
stroke prevention
venous thromboembolism
left atrial thrombus
atrial fibrillation
heart valve diseases

Authors:

Kondratieva T.B.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia

Popova L.V.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia

Bokarev I.N.

kafedra gospital'noĭ terapii Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

List of references:

  1. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GYH, Morais J, Rasmussen LH, Siegbahn A, Verheugt FWA, Weitz JI, De Caterina R et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESCWorking Group on Thrombosis — Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;110:1087-1107. https://doi.org/10.1160/TH13-06-0443
  2. Alison E, Baird PhD, Hart RG et al. Cardiotmbolic stroke. Cerebrovascular Disease. 1998;2:1392-1429. https://doi.org/10.1007/978-0-387-72573-4_31
  3. Robert G Hart, Lesly A Pearce, Maria I Aguilar, Hart RG et al. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med. 2007;147:590-592. https://doi.org/10.7326/0003-4819-147-8-200710160-00018
  4. Connolly SJ et al. AVERROES Steering Committee Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-817. https://doi.org/10.1517/13543784.2012.696611
  5. Susan Colilla, PhD, MPH Ann Crow, MLS William Petkun, MD. Correspondence information about the author MD William Petkunl the author MD William Petkun Daniel E. Singer, MD Teresa Simon, MPH Xianchen Liu, MD, PhD Colilla S et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112:1142-1147. https://doi.org/10.1016/j.amjcard.2013.05.063
  6. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S Zoni-Berisso M et al. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014;6:213-220. https://doi.org/10.2147/CLEP.S47385
  7. Kirchhof P et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37:2893-2962. https://doi.org/10.1136/heartjnl-2016-310843
  8. Szekely P. Systemic Embolism and Anticoagulant Prophylaxis in Rheumatic Heart Disease. Br Med J. 1964;1:1209-1212. https://doi.org/10.1136/bmj.1.5392.1209
  9. Whitlock RP et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e576S-600S. https://doi.org/10.1378/chest.141.4.1129b
  10. John W Eikelboom, Stuart J Connolly, Martina Brueckmann, Christopher B Granger, Arie P Kappetein, Michael J Mack, Jon Blatchford, Kevin Devenny, Jeffrey Friedman, Kelly Guiver, Ruth Harper, Yasser Khder, Maximilian T Lobmeyer, Hugo Maas, Jens-Uwe Voigt, Maarten L Simoons, Frans Van de Werf for the RE-ALIGN Investigators Eikelboom JW et al. for the RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206-1214. https://doi.org/10.1056/NEJMoa1300615
  11. Vahanian A et al. Guidelines on the management of valvular heart disease (version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2012;33:2451-2496. https://doi.org/10.3410/f.718396448.793499638
  12. Breithardt G et al. ROCKET AF Steering Committee & Investigators. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J. 2014;35:3377-3385. https://doi.org/10.1093/eurheartj/ehu305
  13. Avezum A et al. Apixaban compared with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the ARISTOTLE trial. Circulation. 2015;132:624-632. https://doi.org/10.1093/eurheartj/eht310.4384
  14. Yi Wan, Carl Heneghan, Rafael Perera, Nia Roberts, Jennifer Hollowell, Paul Glasziou, Clare Bankhead, Yongyong Xu Wan Y et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation:a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1:84-91. https://doi.org/10.1161/CIRCOUTCOMES.108.796185
  15. Gallego P, Roldan V, Marín F, Romera M, Valdés M, Vicente V, Lip GYH, Gallego P. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost. 2013;110:1189-1198. https://doi.org/10.1160/th13-07-0556
  16. Sjogren V et al. Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. Thromb Haemost. 2015;113:1370-1377. https://doi.org/10.1160/th16070001
  17. Stavros Apostolakis, Renee M Sullivan, Brian Olshansky, Gregory YH, Lip Apostolakis S et al. Factors affecting quality of anticoagulation control amongst atrial fibrillation patients on warfarin: the SAMe-TT2R2 score. Chest. 2013;144:1555-1563. https://doi.org/10.1378/chest.13-0054
  18. Christopher J Bjerkelund, Otto M Orning, Bjerkelund CJ et al. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol. 1969;23:208-216. https://doi.org/10.1016/0002-9149(69)90068-x
  19. January CT et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071-2104. https://doi.org/10.1161/CIR.0000000000000040
  20. Gallagher MM, Hennessy BJ, Edvardsson N, Gallagher MM et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol. 2002;40:926-933. https://doi.org/10.1016/S1062-1458(02)01057-7
  21. Camm AJ et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-2429. https://doi.org/10.12968/bjca.2011.6.5.240
  22. Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens T H, Flaker G, Brugada J, Kamensky G, Parekh A, Reilly P A, Yusuf S, Connolly SJ, Nagarakanti R et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123:131-136. https://doi.org/10.1161/circulationaha.110.977546
  23. Wallentin L, Hijazi Z, Andersson U, Alexander JH, Caterina R De, Hanna M, Horowitz JD, Hylek EM, Lopes RD, Asberg S, Granger CB, Siegbahn A, on behalf of the ARISTOTLE Investigators Flaker G et al. ARISTOTLE Committees and Investigators. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014;63:1082-1087. https://doi.org/10.1161/circulationaha.114.011204
  24. Piccini JP. ROCKET AF Steering Committee & Investigators. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin inthe ROCKET AF trial. J Am Coll Cardiol. 2013;61:1998-2006. https://doi.org/10.1016/j.jacc.2013.02.025
  25. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma C-S, Le Heuzey J-Y, Talajic M, Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van Eickels M, Hohnloser SH, on behalf of the X-VeRT Investigators Cappato R., et al.Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35:3346-3355. https://doi.org/10.1093/eurheartj/ehu367
  26. Cappato R, Calkins H, Chen S-A, Davies W, Iesaka Y, Kalman J, Kim Y-H, Klein G, Natale A, Packer D, Skanes A, Ambrogi F, Biganzoli E, Cappato R et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3:32-38. https://doi.org/10.1161/circep.109.859116
  27. Jonas Bjerring Olesen, Gregory YH Lip, Anne-Lise Kamper, Kristine Hommel, Lars Køber, Deirdre A Lane, Jesper Lindhardsen, Gunnar Hilmar Gislason, Christian Torp-Pedersen Olesen JB et al.Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367:625-635.
  28. Albertsen IE, Rasmussen LH, Overvad TF, Graungaard T, Lar-sen TB, Lip GYH, Larsen TB et al. Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: A systematic review and meta-analysis. Stroke. 2013;44:1329-1336. https://doi.org/10.1161/strokeaha.113.000883
  29. Hart RG, Pearce LA, Asinger RW, Herzog CA, Hart RG, et al. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:2599-2604. https://doi.org/10.2215/cjn.02400311
  30. Friberg L, Benson L, Lip G YH, Friberg L et al. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J. 2014:36:297-306. https://doi.org/10.1093/eurheartj/ehu139
  31. Jun M, James MT, Manns BJ, Quinn RR, Ravani P, Tonelli M, Perkovic V, Winkelmayer WC, Ma Z, Hemmelgarn BR, for the Alberta Kidney Disease Network Jun M et al. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. BMJ. 2015;350:h246. https://doi.org/10.1136/bmj.h246
  32. Zimmerman D, Sood MM, Rigatto C, Holden RM, Hiremath S, Clase CM, Zimmerman D et al. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant. 2012;27:3816-3822. https://doi.org/10.1093/ndt/gfs416
  33. Ricarda Marinigh, Deirdre A Lane, Gregory YH, Lip Marinigh R et al. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol. 2011;57:1339-1348. https://doi.org/10.1016/j.jacc.2010.12.013
  34. Volker Wizemann, Lin Tong, Sudtida Satayathum, Alex Disney, Takashi Akiba, Rachel B Fissell, Peter G Kerr, Eric W Young, Bruce M Robinson Wizemann V et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int. 2010;77:1098-1106. https://doi.org/10.1038/ki.2009.477
  35. Chan KE, Lazarus JM, Thadhani R, Hakim RM, Chan KE et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20:2223-2233. https://doi.org/10.1681/asn.2009030319
  36. Anders Nissen Bonde, Gregory YH Lip, Anne-Lise Kamper, Peter Riis Hansen, Morten Lamberts, Kristine Hommel, Morten Lock Hansen, Gunnar Hilmar Gislason, Christian Torp-Pedersen, Jonas Bjerring Olesen Bonde AN et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol. 2014;64:2471-2482 https://doi.org/10.1016/j.jacc.2014.09.051
  37. Serdechno-sosudistyi risk i khronicheskaya bolezn’ pochek: strategiya kardionefro-protektsii. Komitet ekspertov Rossiiskogo kardiologicheskogo obshchestva (RKO), Nauchnogo obshchestva Rossii (NONR), Rossiiskoi assotsiatsiei endokrinologov (RAE), Rossiiskogo meditsinskogo obshchestva po arterial’noi gipertonii (RMOAG), Rossiiskogo nauchnogo meditsinskogo obshchestva terapevtov (RNMOT). Rossiiskii kardiologicheskii zhurnal. 2014;112(8):7-37. (In Russ.).
  38. Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW, Chan KE, et al. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015;131:972-979. https://doi.org/10.1161/circulationaha.114.014113
  39. Lip GYH, Piotrponikowski P, Andreotti F, Anker SD, Filippatos G, Homma S, Morais J, Pullicino P, Rasmussen LH, Marín F, Lane D A, Lip GYH et al. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Thromb Haemost. 2012;108:1009-1022. https://doi.org/10.1160/th12-08-0578
  40. Stanley Snowden, Lauren Silus Snowden S et al. Oral anticoagulation with warfarin for patients with left ventricular systolic dysfunction. Cardiol Rev. 2011;19:36-40. https://doi.org/10.1097/crd.0b013e318200166d
  41. Stratton JR, Resnick AD et al. Increased embolic risk in patients with left ventricular thrombi. Circulation. 1987;75:1004-1011. https://doi.org/10.1161/01.cir.75.5.1004
  42. Alexander GG Turpie, John G Robinson, Daniel J Doyle, Amin S Mulji, Gregory J Mishkel, Brian J Sealey, John A Cairns, Leslie Skingley, Jack Hirsh, Michael GentTurpie AG et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med. 1989;320:352-357. https://doi.org/10.1056/nejm198902093200604
  43. Barry M Massie, William F Krol, Susan E Ammon, Paul W Armstrong, John G Cleland, Joseph F Collins, Michael Ezekowitz, Syed M Jafri, Christopher M O’Connor, Milton Packer, Kevin A Schulman, Koon Teo, Stuart Warren Massie BM et al. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail. 2004;10:101-112. https://doi.org/10.1016/j.cardfail.2004.02.006
  44. Cleland JGF, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C, Prentice C, Ford I, Trainer Adele, Poole-Wilson PA, Cleland JGF et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J. 2004;148:157-164. https://doi.org/10.1016/j.ahj.2004.03.010
  45. Dennis V Cokkinos, George C Haralabopoulos, John B Kostis, Pavlos K Toutouzas, for the HELAS investigators Cokkinos DV et al. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail. 2006;8:428-432. https://doi.org/10.1016/j.ejheart.2006.02.012
  46. Kearon C et al. Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-352. https://doi.org/10.1016/j.chest.2016.08.1442
  47. Ansell J. New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation. Circulation. 2012;125:165-170. https://doi.org/10.1161/circulationaha.111.031153
  48. Christensen TD, Hasenkam JM, Larsen TB, Christensen TD et al. Letter by Christensen et al. regarding article, «New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation». Circulation. 2012;126:e45. https://doi.org/10.1161/circulationaha.112.098657
  49. Njaastad AM, Abildgaard U, Lassen JF, Njaastad AM et al. Gains and losses of warfarin therapy as performed in an anticoagulation clinic. J Intern Med. 2006;259:296-304. https://doi.org/10.1111/j.1365-2796.2005.01605.x
  50. Poller L et al. Screening computer-assisted dosage programs for anticoagulation with warfarin and other vitamin K-antagonists: minimum safety requirements for individual programs. On behalf of the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the ISTH. J Thromb Haemost. 2009;7:1736. https://doi.org/10.1111/j.1538-7836.2009.03558.x

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.